Table 3.
Univariate Analysis of Risk Factors for Mortality
| Survivors: N 24 | Non-survivors: N 10 | p-value (absolute difference; 95% CI) | |
|---|---|---|---|
| Male | 8 (33%) | 5 (50%) | 0.4 (-0.17; -0.52 to 0.19) |
| Mean age, years (range) | 47.7(3–68) | 52 (35–68) | 0.6 (-4.30; -14.9 to 6.32)a |
| Acute leukemia | 19 (79%) | 9 (90%) | 0.41 (-0.11; -0.35 to 6.32) |
| - Myeloid | 14 (58%) | 8 (80%) | 0.21 (-0.22; -0.53 to 0.10) |
| Other hematological disease | 5 (21%) | 1 (10%) | 0.41 (-0.21; -0.53 to 0.10) |
| Intensive chemotherapy | 20 (83%) | 8 (80%) | 0.58 (0.03; -0.25 to 0.32) |
| Other chemotherapy | 1 (4%) | – | 0.70 (0.04;-0.03 to 0.12) |
| Allogeneic stem cell transplant | 3 (12%) | 2 (20%) | 0.46 (-0.08; -0.35 to 0.20) |
| Length of neutropenia episode (mean days, range) | |||
| - With < 1000 neutrophils/mmc | 19.4 (5–40) | 18.9 (8–35) | 0.70 (0.50; -5.90 to 6.90)a |
| - With < 100 neutrophils/mmc | 11.2 (5–25) | 8.3 (0–17) | 0.29 (2.90; -3.29 to 9.09)a |
| Onset of KPC-K.pneumoniae BSI | |||
| - Shock | 10 (42%) | 7 (70%) | 0.12 (-0.28;-0.62 to 0.06) |
| -< 100 neutrophils/mmc | 21 (87%) | 8 (80%) | 0.61 (0.07; -0.20 to 0.35) |
| - KPC-K.pneumoniae BSI developing during inactive antibiotic treatmentb | 3 (12.5%) | 8 (80%) | < 0.01 (-0.67;-0.95 to -0.39) |
| Active initial treatment | 23 (96%) | 3 (30%) | < 0.01 (-0.76; -1.02 to -0.50) |
| - Combination | 20 (83%) | 2 (20%) | < 0.01 (0.63; 0.34 to 0.92) |
| With colistin | 10 | 1 | 0.07 (0.32; 0.04 to 0.58) |
| With ceftazidime/avibactam | 10 | 1 | 0.07 (0.32; 0.04 to 0.58) |
| - Monotherapy | 3 (12.5%) | 1 (10%) | 0.66 (0.02; -0.20 to 0.25) |
| Tigecyclinec | 2 (8.5%) | 1 (10%) | 0.66 (-0.16;-0.23 to 0.20) |
| Ceftazidime/avibactam | 1 (4.5%) | – | 0.70 (0.4; -0.03 to 0.12) |
| Study period | |||
| - Period 1 (March 2012–Dec 2013) | 9 (37.5%) | 9 (90%) | < 0.01 (− 0.52; − 0.79 to − 0.25) |
| - Period 2 (Jan 2017–Oct 2018) | 15 (62.5%) | 1 (10%) | < 0.01 (0.52; 0.25 to 0.79) |
aContinuous variables were compared using Kruskal–Wallis test
bDeveloped in KPC-K.pneumoniae carriers already receiving standard empiric antibiotic treatment
cCombined with piperacillin/tazobactam as empiric treatment of febrile neutropenia [14]